天津医药

天津医药 ›› 2015, Vol. 43 ›› Issue (3): 282-284.doi: 10.11958/j.issn.0253-9896.2015.03.016

• 临床研究 • 上一篇    下一篇

外周 T 细胞淋巴瘤患者外周血中髓源性抑制细胞的表达及意义

李艳丽,卜庆   

  1. 桂林医学院附属医院肿瘤内科 （邮编541004）
  • 收稿日期:2014-09-10 修回日期:2014-11-12 出版日期:2015-03-15 发布日期:2015-03-15
  • 通讯作者: 卜庆 E-mail:794847079@qq.com
  • 作者简介:广西自然科学基金青年基金项目 （2011GXNSFB018092）
  • 基金资助:
    广西自然科学基金青年基金项目 （2011GXNSFB018092）

The expression and significance of MDSCs in peripheral blood in patients with peripheral T cell lymphoma

LI Yanli, Bu Qing   

  1. Department of Medical Oncology, the Affiliated Hospital of Guilin Medical University, Guilin 541000, China

  • Received:2014-09-10 Revised:2014-11-12 Published:2015-03-15 Online:2015-03-15
  • Contact: Bu Qing E-mail:794847079@qq.com

PDF (PC)

3896

摘要： 目的 探索外周 T 细胞淋巴瘤（PTCL）患者外周血中髓源性抑制细胞（MDSCs）数量与预后的关系。方法 收集 PTCL 患者 23 例,选取 14 例同期健康体检者作为正常对照组,采用流式细胞仪检测其外周血 MDSCs/单核细胞比例, 分析 MDSCs 数量与 PTCL 患者预后及临床特征的关系。结果 MDSCs 在 PTCL 患者外周血单核细胞中所占的比例高于正常对照组[(4.59±1.41)% vs (1.36±0.59)%, P < 0.01]。PTCL 化疗后外周血 MDSCs 的表达（1.29± 2.95） %较化疗前明显降低。结外侵犯部位、 骨髓侵犯、 临床分期、 IPI 评分不同的 PTCL 患者外周血 MDSCs 的表达差异有统计学意义 （P<0.05）。结论 MDSCs 在 PTCL 患者外周血中高表达,提示与肿瘤发生及预后不良有关。

关键词: 淋巴瘤, T 细胞, 外周, 流式细胞术, 髓源性抑制细胞

Abstract: Objective To study the relationship between the number of myeloid-derived suppressor cells (MDSCs) in peripheral blood and prognosis in patients with peripheral T-cell lymphoma (PTCL). Methods Twenty-three patients with PTCL were selected in this study and 14 healthy persons were used as the normal control. The proportion of MDSCs/ mononu⁃ clear in peripheral blood was detected by flow cytometry. The correlation between the number of MDSCs and the clinical character and prognosis in patients with PTCL was analyzed. Results The proportion of MDSCs in peripheral blood was sig⁃ nificantly higher in patients with PTCL than that of healthy subjects [(4.59±1.41)% vs (1.36±0.59)%, P < 0.01]. The number of MDSCs in peripheral blood was significantly decreased after chemotherapy compared with that before treatment [(1.29 ± 2.95)%, P < 0.05)]. There were significant differences in MDSCs expressions in patients between different extranodal involve⁃ ment, bone marrow involvement, clinical stage and IPI score (P < 0.05). Conclusion The higher expression of MDSCs may be related to the progression in patients with PTCL.

Key words: lymphoma, T-cell, peripheral, flow cytometry, myeloid-derived suppressor cells